Ibogaine-related compounds and corresponding methods

Abstract

The present invention relates to Ibogaine derivatives and related methods. It more specifically relates to deutero- and fluoro-derivatives of Ibogaine and related methods. In one aspect, the present invention provides a compound. The structure of the compound is shown as compound 1 in FIG. 1. In another aspect, the present invention provides a method of treating an addiction disorder. The method comprises administration of compound 1. In another aspect, the present invention provides a method of treating an anxiety-related disorder or impulse control disorder. The method comprises administration of compound 1.

Description

FIELD OF THE INVENTION

The present invention relates to Ibogaine derivatives and related methods. It more specifically relates to deutero- and fluoro-derivatives of Ibogaine and related methods.

BACKGROUND OF THE INVENTION

There have been reports of Ibogaine derivatives. U.S. Pat. No. 6,780,871, entitled “Methods and compositions for treating addiction disorders” allegedly reports the following: “A method for treating an addiction disorder (such as an addiction to or dependency on stimulants, nicotine, morphine, heroin, other opiates, amphetamines, cocaine, and/or alcohol) in a patient is disclosed. The method includes administering to the patient a first α₃β₄ nicotinic receptor antagonist and administering to the patient a second α₃β₄ nicotinic receptor antagonist. The second α₃β₄ nicotinic receptor antagonist is different than the first α₃β₄ nicotinic receptor antagonist, and the first α₃β₄ nicotinic receptor antagonist and the second α₃β₄ nicotinic receptor antagonist are administered simultaneously or non-simultaneously. Compositions which include a first α₃β₄ nicotinic receptor antagonist and a second α₃β₄ nicotinic receptor antagonist are also described. Examples of suitable α₃β₄ nicotinic receptor antagonists for use in the present invention's methods and compositions include mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts and solvates thereof. A method of evaluating a compound for its effectiveness in treating addiction disorders is also described.” Abstract.

U.S. Pat. No. 9,592,239, entitled “Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake” allegedly discusses the following: “This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and/or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof” Abstract.

Despite the reports, there is still a need for novel Ibogaine-related compounds and corresponding methods.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a compound. The structure of the compound is shown as compound 1 in FIG. 1. The substituents for compound 1 are as follows: R₁ is H, D, OH, CH₂OH, CD₂OH, CH₂CH₂OH, CH₂CD₂OH, CD₂CD₂OH, OCH₃, OCDH₂, OCD₂H, OCD₃, CH₂OCDH₂, CH₂OCD₂H, CH₂OCD₃, CH₂CH₂OCDH₂, CH₂CH₂OCD₂H, CH₂CH₂OCD₃, CH₂CD₂OCDH₂, CH₂CD₂OCD₂H, CH₂CD₂OCD₃, CD₂CD₂OCDH₂, CD₂-CD₂OCD₂H, CD₂CD₂OCD₃, CH₂CH₂OCH₂OCH₂CH₂OCH₃, CH₂CH₂OCH₂OCH₂CH₂OCDH₂, CH₂CH₂OCH₂OCH₂CH₂O—CD₂H, CH₂CH₂OCH₂OCH₂CH₂OCD₃, CH₂CH₂OCH₂OCH₂CD₂-OCD₃, CH₂CH₂OCH₂OCD₂CD₂OCD₃, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CH₂O—CH₂CH₂OCH₂CH₂OCDH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂OCD₂H, CH₂CH₂OCH₂CH₂OCH₂CH₂—OCD₃, CH₂CH₂OCH₂CH₂OCH₂CD₂OCD₃, CH₂CH₂OCH₂CH₂OCD₂CD₂OCD₃, OCF₃, CH₂OCF₃, or CD₂OCF₃; R₂ is H, D, CO₂H, CO₂R₁₂ where R₁₂ is a pharmaceutically acceptable salt (e.g., sodium, fumaric, etc.), CO₂CH₃, CO₂CH₂D, CO₂CHD₂, CO₂CD₃, CO₂CH₂CH₃, CO₂CH₂CD₃, CO₂CD₂CD₃, C(O)NH₂, C(O)NHCH₃, C(O)NHCD₃, C(O)N(CH₃)₂, C(O)N(CH₃)(CD₃), or C(O)N(CD₃)₂; R₃ is H, C(O)OCH₃, C(O)OCD₃, C(O)CH₂CH₃, C(O)CH₂CD₃, C(O)CD₂CD₃, C(O)OCH₂CH₂OCH₃, C(O)OCH₂CH₂OCD₃, C(O)OCH₂CD₂OCD₃, C(O)OCD₂CD₂OCD₃, or C(O)OCF₃; R₄ is H, D, F, Cl, Br, I, CH₃, CF₃, CH₂CH₃, CO₂H, CO₂CH₃, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂, OH, OCH₃, OCD₃, or CN; R₅ is H, D, F, Cl, Br, I, CH₃, CF₃, CH₂CH₃, CO₂H, CO₂CH₃, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂, OH, OCH₃, OCD₃, or CN; R₆ is H or D; R₇ is H or D; R₈ is H or D; R₉ is H or D; R₁₀ is H or D; R₁₁ is H or D; “n” is an integer selected from 1, 2, 3, 4, 5, 6, 7 and 8.

In another aspect, the present invention provides a method of treating an addiction disorder. The method comprises administration of compound 1 as discussed above.

In another aspect, the present invention provides a method of treating an anxiety-related disorder or impulse control disorder. The method comprises administration of compound 1 as discussed above.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1-6 show examples of compounds according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention typically include deuterium in an amount that is more than expected from isotopic abundance. This deuterium enrichment can be shown by inclusion of “D” in a chemical structure. Typically, in the case of deuterium enrichment, the amount of deuterium (e.g., where “D” is indicated), as opposed to protium or tritium, is more than 20 percent, more than 30 percent, more than 40 percent, more than 50 percent, more than 60 percent, more than 70 percent, more than 80 percent, more than 90 percent or more than 95 percent.

Examples of compounds of the present invention are shown in FIGS. 1-6. Regarding compound 1 in FIG. 1, substituents are as follows: R₁ is H, D, OH, CH₂OH, CD₂OH, CH₂CH₂OH, CH₂CD₂OH, CD₂CD₂OH, OCH₃, OCDH₂, OCD₂H, OCD₃, CH₂OCDH₂, CH₂OCD₂H, CH₂OCD₃, CH₂CH₂OCDH₂, CH₂CH₂OCD₂H, CH₂CH₂OCD₃, CH₂CD₂OCDH₂, CH₂CD₂OCD₂H, CH₂CD₂OCD₃, CD₂CD₂OCDH₂, CD₂-CD₂OCD₂H, CD₂CD₂OCD₃, CH₂CH₂OCH₂OCH₂CH₂OCH₃, CH₂CH₂OCH₂OCH₂CH₂OCDH₂, CH₂CH₂OCH₂OCH₂CH₂O—CD₂H, CH₂CH₂OCH₂OCH₂CH₂OCD₃, CH₂CH₂OCH₂OCH₂CD₂-OCD₃, CH₂CH₂OCH₂OCD₂CD₂OCD₃, CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₃, CH₂CH₂O—CH₂CH₂OCH₂CH₂OCDH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂OCD₂H, CH₂CH₂OCH₂CH₂OCH₂CH₂—OCD₃, CH₂CH₂OCH₂CH₂OCH₂CD₂OCD₃, CH₂CH₂OCH₂CH₂OCD₂CD₂OCD₃, OCF₃, CH₂OCF₃, or CD₂OCF₃; R₂ is H, D, CO₂H, CO₂R₁₂ where R₁₂ is a pharmaceutically acceptable salt (e.g., sodium, fumaric, etc.), CO₂CH₃, CO₂CH₂D, CO₂CHD₂, CO₂CD₃, CO₂CH₂CH₃, CO₂CH₂CD₃, CO₂CD₂CD₃, C(O)NH₂, C(O)NHCH₃, C(O)NHCD₃, C(O)N(CH₃)₂, C(O)N(CH₃)(CD₃), or C(O)N(CD₃)₂; R₃ is H, C(O)OCH₃, C(O)OCD₃, C(O)CH₂CH₃, C(O)CH₂CD₃, C(O)CD₂CD₃, C(O)OCH₂CH₂OCH₃, C(O)OCH₂CH₂OCD₃, C(O)OCH₂CD₂OCD₃, C(O)OCD₂CD₂OCD₃, or C(O)OCF₃; R₄ is H, D, F, Cl, Br, I, CH₃, CF₃, CH₂CH₃, CO₂H, CO₂CH₃, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂, OH, OM, OCD₃, or CN; R₅ is H, D, F, Cl, Br, I, CH₃, CF₃, CH₂CH₃, CO₂H, CO₂CH₃, C(O)NH₂, C(O)NHCH₃, C(O)N(CH₃)₂, OH, OCH₃, OCD₃, or CN; R₆ is H or D; R₇ is H or D; R₈ is H or D; R₉ is H or D; R₁₀ is H or D; R₁₁ is H or D; “n” is an integer selected from 1, 2, 3, 4, 5, 6, 7 and 8.

Compounds of the present invention can be used to treat a variety of disorders, including, without limitation, the following: an addiction disorder (e.g., addiction to or dependency on stimulants, nicotine, morphine, heroin, other opiates, amphetamines, cocaine and/or alcohol); an anxiety-related disorder or impulse control disorder, regulating food intake (e.g., obesity), attenuating food cravings, or treating anger and/or violence and disorders associated therewith.

Compounds of the present invention can be synthesized using methods known to one of ordinary skill in the art. Nonlimiting examples of such methods, using known compounds and intermediates—as seen and discussed in U.S. Pat. Nos. 6,780,871, 8,993,559, 9,592,239, 6,211,360 and Bornmann, et al., J. Org. Chem., 57:1752 (1992)—can be found in the following articles: Miyashita, M.; Sasaki, M.; Hattori, I.; Sakai, M.; Tanino, K. Science 2004, 305, 495; Foster, A. B. Trends Pharmacol. Sci. 1984, 5, 524; Kushner, D. J.; Baker, A.; Dunstall, T. G. Can. J. Physiol. Pharmacol. 1999, 77, 79; Harbeson, S. L.; Tung, R. D. Annu. Rep. Med. Chem. 2011, 46, 403; Meanwell, N. A. J. Med. Chem. 2011, 54, 2529; Phillips, D. H.; Potter, G. A.; Horton, M. N.; Hewer, A.; Crofton-Sleigh, C.; Jarman, M.; Venitt, S. Carcinogenesis 1994, 15, 1487; Jarman, M.; Poon, G. K.; Rowlands, M. G.; Grimshaw, R. M.; Horton, M. N.; Potter, G. A.; McCague, R. Carcinogenesis 1995, 16, 683; Mutlib, A. E.; Gerson, R. J.; Meunier, P. C.; Haley, P. J.; Chen, H.; Gan, L. S.; Davies, M. H.; Gemzik, B.; Christ, D. D. et al. Toxicol. Appl. Pharmacol. 2000, 169, 102; Mutlib, A. E.; Gerson, R. J.; Meunier, P. C.; Haley, P. J.; Chen, H.; Gan, L. S.; Davies, M. H.; Gemzik, B.; Christ, D. D. et al. Toxicol. Appl. Pharmacol. 2000, 169, 102; Maltais, F.; Jung, Y. C.; Chen, M.; Tanoury, J.; Perni, R. B.; Mani, N.; Laitinen, L.; Huang, H.; Liao, S.; Gao, H. et al. J. Med. Chem. 2009, 52, 799; Katsnelson, A. Nature Med. 2013, 19, 656; Atzrodt, J.; Derdau, V.; Fey, T.; Zimmermann, J. Angew. Chem. Int. Ed. 2007, 46, 7744; Atzrodt, J.; Derdau, V. J. Label. Compd. Radiopharm. 2010, 53, 67; Kluger, R. J. Org. Chem. 1964, 29, 2045; Paulsen, P. J.; Cooke, W. D. Anal. Chem. 1963, 35, 1560; Yung, C. M.; Skaddan, M. B.; Bergman, R. G. J. Am. Chem. Soc. 2004, 126, 13033; Skaddan, M. B.; Yung, C. M.; Bergman, R. G. Org. Lett. 2004, 6, 11; Heys, R. J. Chem. Soc., Chem. Commun. 1992, 68; Shu, A. Y. L.; Chen, W.; Heys, J. R. J. Organomet. Chem. 1996, 524, 87; Ma, S.; Villa, G.; Thuy-Boun, P. S.; Horns, A.; Yu, J.-Q. Angew. Chem. Int. Ed. 2014, 53, 734; Zhou, J.; Hartwig, J. F. Angew. Chem. Int. Ed. 2008, 47, 578; Takahashi, M.; Oshima, K.; Matsubara, S. Chem. Lett. 2005, 34, 19; Neubert, L.; Michalik, D.; Balm, S.; Imm, S.; Neumann, H.; Atzrodt, J.; Derdau, V.; Holla, W.; Beller, M. J. Am. Chem. Soc. 2012, 134, 12239; Sajiki, H.; Ito, N.; Esaki, H.; Maesawa, T.; Maegawa, T.; Hirota, K. Tetrahedron Lett. 2005, 46, 6995; Sajiki, H.; Aoki, F.; Esaki, H.; Maegawa, T.; Hirota, K. Org. Lett. 2004, 6, 1485. The preceding articles and patents are incorporated-by-reference into this document for all purposes. For the synthesis of trifluoromethyl ethers and related compounds, see, for example: Leroux et al., Beilstein J Org. Chem. 2008, 4, No. 13, which is incorporated-by-reference into this document for all purposes.

Suitable dosage forms for oral use include tablets, dispersible powders, granules, capsules, suspensions, syrups, and elixirs. Inert diluents and carriers for tablets include, for example, calcium carbonate, sodium carbonate, lactose, and talc. Tablets may also contain granulating and disintegrating agents, such as starch and alginic acid; binding agents, such as starch, gelatin, and acacia; and lubricating agents, such as magnesium stearate, stearic acid, and talc. Tablets may be uncoated or may be coated by known techniques to delay disintegration and absorption. Inert diluents and carriers which may be used in capsules include, for example, calcium carbonate, calcium phosphate, and kaolin. Suspensions, syrups, and elixirs may contain conventional excipients, such as methyl cellulose, tragacanth, sodium alginate; wetting agents, such as lecithin and polyoxyethylene stearate; and preservatives, such as ethyl-p-hydroxybenzoate.

Dosage forms suitable for parenteral administration include solutions, suspensions, dispersions, emulsions, microcapsules and the like. They may also be manufactured in the form of sterile solid compositions which can be dissolved or suspended in sterile injectable medium immediately before use. They may contain suspending or dispersing agents known in the art. Where microcapsules are employed, they can be readily prepared by conventional microencapsulation techniques, such as those disclosed in, for example, Encyclopedia of Chemical Technology, 3rd edition, volume 15, New York: John Wiley and Sons, pp. 470-493 (1981), which is hereby incorporated by reference.

Preferably, a compound or composition according to the present invention is administered in amounts that are effective to treat a patient's disorder. Illustratively, a compound or composition can be administered in an amount from about 0.01 to about 10 mg/kg of the patient's body weight per day. In certain cases, the compound or composition can be administered in an amount from about 0.02 to about 5 mg/kg of the patient's body weight per day or in an amount from about 0.1 to about 5 mg/kg of the patient's body weight per day.

Claims

1. A compound, wherein the compound is of the following structure:

2. A method of treating nicotine addiction comprising administration of a compound according to claim 1.

3. A method of treating food cravings comprising administration of a compound according to claim 1.